Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease

doi:10.12998/wjcc.v9.i36.11285

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 36

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6381)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

395

WORD

115

HTML

2678

Figures (1-2)

571

Tables (1-5)

380

Sum=4139

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

466

Download

1776

Sum=2242

Dec 26, 2021 (publication date) through May 14, 2025

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Clin Cases. Dec 26, 2021; 9(36): 11285-11299
Published online Dec 26, 2021. doi: 10.12998/wjcc.v9.i36.11285

Table 3 Montreal classification of Crohn’s disease and ulcerative colitis at baseline, n (%)

Montreal classification of CD	CD (n = 133)
Age of diagnosis
A1 (below 16 yr)	15 (11)
A2 (between 17 and 40 yr)	90 (68)
A3 (above 40 yr)	18 (14)
-	10 (8)
Location
L1 (ileal)	62 (47)
L2 (colonic)	16 (12)
L3 (ileocolonic)	47 (35)
-	8 (6)
Location L4¹ (concomitant UGI disease)
Yes	4 (3)
No	87 (65)
-	42 (32)
Behavior
B1 (non-stricturing, non-penetrating)	60 (45)
B2 (stricturing)	24 (18)
B3 (penetrating)	38 (29)
-	11 (8)
P² (concomitant perianal disease)
Yes	38 (29)
No	84 (63)
-	11 (8)
Montreal classification of UC	UC (n = 87)
Extent
E1 (Ulcerative proctitis)	10 (11)
E2 (Left-sided UC - distal UC)	18 (21)
E3 (Extensive UC - pancolitis)	48 (55)
-	11 (13)
Severity
S1 (Mild UC)	8 (9)
S2 (Moderate UC)	54 (62)
S3 (Severe UC)	15 (17)
-	10 (11)

¹May coexist with L1–L3.

²May coexist with B1–B3.

CD: Crohn’s disease; UC: Ulcerative colitis; UGI: Upper gastrointestinal.

Citation: Huguet JM, Cortés X, Bosca-Watts MM, Aguas M, Maroto N, Martí L, Amorós C, Paredes JM. Real-world data on the infliximab biosimilar CT-P13 (Remsima^®) in inflammatory bowel disease. World J Clin Cases 2021; 9(36): 11285-11299
URL: https://www.wjgnet.com/2307-8960/full/v9/i36/11285.htm
DOI: https://dx.doi.org/10.12998/wjcc.v9.i36.11285